Literature DB >> 9672967

FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls.

H J Vesselle1, F D Miraldi.   

Abstract

Evaluation of the retroperitoneum is important to assess the extent of retroperitoneal malignancies and because the retroperitoneum is a route of nodal spread for other malignancies. Positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) allows detection of small malignant nodes not identified or not meeting size criteria for malignancy with computed tomography (CT) and tumor recurrences in surgical beds that are otherwise difficult to assess. However, evaluation of retroperitoneal malignancies or adenopathy with FDG PET can be complicated by urinary and colonic activity or anatomic variants. Urinary artifacts are avoided with intravenous hydration, administration of furosemide, and catheterization and retrograde filling of the bladder with saline solution. Colonic artifacts are avoided by cleansing the bowel with an isosmotic solution. FDG PET is useful in assessing the retroperitoneum for adenopathy in malignancies such as testicular cancer; lymphoma; and rectal ovarian, or cervical cancer that spread along retroperitoneal lymphatics. FDG PET is especially useful for detection of malignant nodes that do not meet size criteria at CT or when lack of retroperitoneal fat makes it difficult to identify retroperitoneal nodes with CT. FDG PET has an important role in evaluation of postoperative beds, where CT has limited useful because of altered anatomy, surgical clip artifacts, and scar issue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672967     DOI: 10.1148/radiographics.18.4.9672967

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  9 in total

Review 1.  Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process.

Authors:  Matthew J Krasin; Melissa M Hudson; Sue C Kaste
Journal:  Pediatr Radiol       Date:  2004-01-27

2.  The incremental value of dual modality PET/CT imaging over PET imaging alone in advanced colorectal cancer.

Authors:  A H Engledow; G E L Bond-Smith; D Francis; F Pakzad; J Bomanji; A Groves; P J Ell
Journal:  Indian J Surg       Date:  2009-05-02       Impact factor: 0.656

3.  Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients.

Authors:  Barbara J Fueger; Wolfgang A Weber; Andrew Quon; Tyler L Crawford; M S Allen-Auerbach; B S Halpern; Osman Ratib; Michael E Phelps; Johannes Czernin
Journal:  Mol Imaging Biol       Date:  2005 Sep-Oct       Impact factor: 3.488

4.  Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography.

Authors:  D H Park; K H Kim; S Y Park; B H Lee; C W Choi; S Y Chin
Journal:  Korean J Radiol       Date:  2000 Jan-Mar       Impact factor: 3.500

5.  Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers.

Authors:  S Harkirat; Ss Anand; Mj Jacob
Journal:  Indian J Radiol Imaging       Date:  2010-02

Review 6.  The role of positron emission tomography in germ cell cancer.

Authors:  Maria De Santis; Jörg Pont
Journal:  World J Urol       Date:  2004-03-16       Impact factor: 4.226

7.  Aneurysm of the inferior vena cava with thrombosis.

Authors:  Masashi Inoue; Takeshi Sudo; Megumi Yamaguchi; Shingo Seo; Tatsuya Miyamoto; Toshihiro Misumi; Wataru Shimizu; Toshimitsu Irei; Takahisa Suzuki; Takashi Onoe; Yosuke Shimizu; Takao Hinoi; Hirotaka Tashiro
Journal:  Clin Case Rep       Date:  2018-01-13

Review 8.  Advances in bladder cancer imaging.

Authors:  Shaista Hafeez; Robert Huddart
Journal:  BMC Med       Date:  2013-04-10       Impact factor: 8.775

9.  Huge Retroperitoneal Cyst Masquerading as Ovarian Tumour: A Case Report.

Authors:  Syamim Johan; Muhammad Firdaus Hassan; Firdaus Hayati; Nornazirah Azizan; Alvin Oliver Payus; Un Hean Edwin See
Journal:  Front Surg       Date:  2020-10-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.